Open AccessUsefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
Author(s) -
M Gil Candel,
Juan José Gascón Cánovas,
E Urbieta Sanz,
Rosa Gómez Espín,
Isabel Nicolás de Prado,
Carles Iniesta Navalón
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6618/2019
Subject(s) - medicine , infliximab , inflammatory bowel disease , therapeutic drug monitoring , drug , inflammatory bowel diseases , disease , gastroenterology , intensive care medicine , pharmacology
previous studies have shown that higher infliximab trough levels are associated with favorable short-term and long-term therapeutic outcomes in inflammatory bowel disease. There is a need to determine which patients could benefit from proactive therapeutic drug monitoring in the induction phase. The aim of this study was to evaluate the pharmacokinetic variability of infliximab, determine the factors associated with achieving target infliximab trough levels in the induction phase and analyze the clinical and biochemical response at week 26 of treatment.